Welcome to our dedicated page for VERACYTE SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERACYTE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERACYTE's regulatory disclosures and financial reporting.
Veracyte, Inc. (VCYT) reported an insider transaction on Form 4. The company’s Chief Financial Officer sold 7,000 shares of common stock at $41 on 11/05/2025, marked with transaction code S. The filing notes the trades were made under a Rule 10b5-1 plan adopted on August 13, 2024.
After the sale, the officer beneficially owns 126,158 shares, held directly.
Veracyte, Inc. reported stronger Q3 2025 results, with total revenue of $131.9 million, up from $115.9 million a year ago. Testing revenue rose to $127.8 million, while product revenue was $3.3 million and biopharmaceutical and other revenue was $0.8 million. Gross profit increased to $91.3 million. Net income was $19.1 million versus $15.2 million last year, and diluted EPS was $0.24 versus $0.19.
Operating expenses were $68.3 million. Other income (loss), net was a loss of $4.1 million, reflecting a $6.7 million loss on deconsolidation of the French subsidiary in August 2025. For the nine months, operating cash flow was $83.7 million, up from $50.6 million. The balance sheet showed cash and cash equivalents of $315.6 million, short‑term investments of $50.9 million, and stockholders’ equity of $1.26 billion as of September 30, 2025. Medicare and UnitedHealthcare represented 33% and 14% of Q3 revenue, respectively. Shares outstanding were 79,049,173 as of October 31, 2025.
Veracyte, Inc. furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The results are provided in a press release attached as Exhibit 99.1.
The company states this information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference unless specifically so stated.
Veracyte, Inc. (VCYT) officer Jonathan Wygant, VP and Chief Accounting Officer, reported an equity award on Form 4. On 10/28/2025, he acquired 2,886 shares of common stock at $0 under transaction code A, reflecting a restricted stock unit grant. Following the transaction, his beneficial ownership stands at 49,665 shares, held directly.
The filing notes the RSUs were awarded on October 28, 2025 and vest in full on the first anniversary of the grant date, subject to his continued employment.
Veracyte, Inc. insider Phillip G. Febbo sold 8,349 shares of common stock on 10/06/2025 at a weighted average price of $36.0174, reducing his beneficial ownership to 92,441 shares. The filing states the sales were made under a Rule 10b5-1 trading plan adopted on 09/04/2024, and individual sale prices ranged from $35.82 to $36.28. The Form 4 was signed by an attorney-in-fact on 10/07/2025. No options or derivative transactions were reported.
Veracyte, Inc. notice reports a proposed sale of 8,349 common shares on NASDAQ with an aggregate market value of $300,564. The shares represent restricted stock units acquired from the issuer on 12/02/2024 and were paid/issued on the same date. The filing states there were 78,671,588 shares outstanding, and the seller reports no securities sold in the prior three months. The sale is planned for 10/06/2025. The filer affirms they are not aware of undisclosed material adverse information and signs the notice consistent with Rule 144 requirements.
Veracyte (VCYT) insider transaction: The company’s Chief Commercial Officer-CLIA reported a sale of 2,539 shares of common stock at $35 on 10/01/2025, coded “S”. The filing notes the trades were made under a Rule 10b5-1 plan adopted on June 9, 2025. Following the transaction, the reporting person beneficially owns 89,099 shares, held directly.
Robert S. Epstein, a director of Veracyte, Inc. (VCYT), reported transactions on a Form 4 dated 10/01/2025. He exercised 10,000 stock options with an exercise price of $7.94, resulting in 10,000 shares issued, and subsequently sold 21,473 common shares at a weighted average sale price of $35.0768 (individual sales ranged $35.00–$35.30). The Form shows his beneficial ownership changing from 83,919 shares after the option exercise to 62,446 shares following the sale. The transactions were made under a Rule 10b5-1 plan adopted June 5, 2025, and the Form was signed by an attorney-in-fact on 10/03/2025.
An officer of Veracyte, Inc. executed a programmed sale of 2,160 shares of the company's common stock on 10/01/2025 under a Rule 10b5-1 trading plan. The sale's weighted average price was approximately $35.00 per share (individual prices ranged $35.00–$35.05), and the reporting person retained beneficial ownership of 89,439 shares after the transactions. The filer notes the sales were made pursuant to a plan adopted on 9/04/2024, and that detailed per-price share counts are available on request.
Veracyte, Inc. filed a Form 144 reporting a proposed sale of 2,539 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 10/01/2025. The filing lists an aggregate market value of $87,163.87 based on 78,671,588 shares outstanding. The shares were acquired on 03/02/2024 as restricted stock units issued by the company and were paid on that same date. The filer reports no securities sold in the past three months and certifies they have no undisclosed material adverse information regarding the issuer.